Friday, August 28 2026

ABOT 1HCY26 profit rises 17%
Abbott Laboratories (Pakistan) Limited (PSX: ABOT) reported a 17% increase in its net profit for the half-year ended June 30, 2026 (1HCY26), reaching Rs4.14bn compared to Rs3.54bn in the corresponding period last year. Reflecting this solid bottom-line growth, basic and diluted earnings per share (EPS) for the six-month period improved to Rs42.29, up from Rs36.19 in 1HCY25. The primary catalyst behind the financial expansion was a combination of steady local revenue growth and expanded gross margins. Net sales grew by 4% year-on-year to Rs38.03bn, up from Rs36.41bn in 1HCY25, as a 6% increase in local sales (Rs37.15bn) offset a 41% decline in export sales (Rs875.69m). Meanwhile, the cost of sales decreased slightly by 1% to Rs23.58bn, enabling gross profit to expand 15% to Rs14.45bn compared to Rs12.61bn in the prior year.
Related news categories: business economic-indicators pharma psx stock-exchanges
Related symbols: abot (news stock)

Tuesday, August 25 2026

Govt approves prices for 52 advanced life-saving drugs
The Pakistan government has approved prices for 52 new essential medicines including those used to treat diseases including cancer, hypertension, diabetes, and respiratory conditions, as well as vaccines for infections. The move will likely improve access of patients to the advanced drugs. “A Cabinet Committee constituted by the Prime Minister for drug pricing that was recently chaired by Federal Minister for Finance and Revenue Muhammad Aurangzeb set pricing for the 52 new molecules to be made available in the market soon,” Pakistan Pharmaceutical Manufacturers Association (PPMA) former chairman Dr Kaiser Waheed said while talking to Business Recorder.
Related news categories: business economic-indicators misc pharma